Keros Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $243.9M | $0 | $151.0K | $0 | $20.1M | $0 | $10.0M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $129.6M | $173.6M | $135.3M | $87.3M | $55.1M | $33.9M | $17.4M |
| SG&A Expense | $46.8M | $40.8M | $34.8M | $27.5M | $21.3M | $12.8M | $3.2M |
| Operating Income | $67.6M | $-210.8M | $-169.9M | $-114.8M | $-56.4M | $-46.7M | $-10.6M |
| Operating Margin | 27.7% | — | -112,543.7% | — | -280.5% | — | -105.6% |
| Interest Expense | — | $0 | $0 | $1.0K | $4.0K | $6.0K | — |
| Pretax Income | $91.9M | $-187.1M | $-153.0M | $-104.7M | $-56.7M | $-45.5M | $-12.3M |
| Income Tax Expense | $4.9M | $300.0K | $0 | $0 | $2.0M | $-172.0K | $0 |
| Net Income | $87.0M | $-187.4M | $-153.0M | $-104.7M | $-58.7M | $-45.4M | $-12.3M |
| Net Margin | 35.7% | — | -101,319.2% | — | -292.3% | — | -123.4% |
| EPS (Basic) | $2.34 | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 | $-6.08 |
| EPS (Diluted) | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 | $-6.08 |
| Shares Outstanding (Basic) | 37.2M | 37.4M | 29.4M | 25.2M | 23.3M | 15.5M | 2.4M |
| Shares Outstanding (Diluted) | 37.9M | 37.4M | 29.4M | 25.2M | 23.3M | 15.5M | 2.4M |
| Dividends Per Share | — | — | — | — | — | — | — |